Table 2.
Sociodemographic and Clinical Characteristics of the Cohort Participants
| Variable | Education |
P-valuea | |
|---|---|---|---|
| Low (n=284) | High (n=21) | ||
| Age (yr) | 0.070 | ||
| < 65 | 190 (66.9) | 18 (87.5) | |
| ≥ 65 | 94 (33.1) | 3 (14.3) | |
| Sex | 0.170 | ||
| Male | 167 (58.8) | 11 (52.4) | |
| Female | 117 (41.2) | 10 (47.6) | |
| Place of origin | 0.002 | ||
| Rural | 189 (66.5) | 7 (33.3) | |
| Urban | 95 (33.5) | 14 (66.7) | |
| Occupation | 0.730 | ||
| Worker | 151 (49.5) | 12 (57.1) | |
| Unemployed | 55 (50.5) | 9 (42.9) | |
| Clinical stage | 0.960 | ||
| Early | 87 (30.6) | 6 (28.6) | |
| Advanced | 153 (53.9) | 12 (57.5) | |
| Unclassified | 44 (15.5) | 3 (14.3) | |
| Location of the tumor | 0.230 | ||
| Blind | 38 (13.5) | 2 (9.5) | |
| Ascending+descending colon | 77 (27.3) | 4 (19.0) | |
| Transverse colon | 17 (7.4) | 4 (19.0) | |
| Sigmoid | 47 (16.7) | 4 (19.0) | |
| Straight | 103 (36.5) | 7 (33.3) | |
| Tumor size (cm) | 0.190 | ||
| 2–5 | 93 (35.8) | 4 (21.1) | |
| > 5 | 167 (64.2) | 15 (78.9) | |
| Metastatic lymph nodes | < 0.001 | ||
| No | 239 (84.2) | 11 (52.4) | |
| Yes | 45 (15.8) | 10 (47.6) | |
| Location of metastasis | 0.030 | ||
| Liver | 40 (41.7) | 1 (33.3) | |
| Lung | 13 (13.5) | 2 (66.7) | |
| Others | 43 (44.8) | 0 | |
| Type of treatment (n = 261) | 0.170 | ||
| Surgery | 18 (18.2) | 1 (5.0) | |
| Chemotherapy | 23 (23.2) | 5 (25.0) | |
| Radiotherapy | 1 (1.0) | 1 (5.0) | |
| Surgery and chemotherapy | 37 (37.4) | 10 (50.0) | |
| Surgery and radiotherapy | 3 (3.0) | 1 (5.0) | |
| Chemotherapy and radiotherapy | 7 (7.1) | 1 (5.0) | |
| Surgery+chemotherapy+radiotherapy | 10 (10.1) | 1 (5.0) | |
| Type of chemotherapy (n = 182) | 0.590 | ||
| Neoadjuvant | 61 (33.5) | 5 (27.8) | |
| Adjuvant | 121 (66.5) | 13 (72.2) | |
| Scheme of chemotherapy (n = 163) | 0.960 | ||
| Oxaliplatin | 59 (39.6) | 5 (35.7) | |
| XELOX | 37 (24.8) | 4 (28.6) | |
| FOLFOX | 15 (10.1) | 2 (14.3) | |
| 5 FU | 20 (13.4) | 16 (14.3) | |
| Others | 18 (12.1) | 1 (7.1) | |
a
Comparison of proportions using chi square (Fisher exact test was used when necessary).
XELOX, capecitabine (Xeloda) and oxaliplatin; 5 FU, 5-fluorouracil; FOLFOX, oxaliplatin, 5-FU, and leucovorin.